Linked Life Data

1531219

Source:http://linkedlifedata.com/resource/pubmed/id/1531219

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1992-3-10
pubmed:abstractText
Thirty-four patients affected by primary pulmonary carcinoma or in a state of recurrence after surgery were analyzed and 2g/m2 of etanidazole was administered intravenously. After 30 min (group A), 60 min (group B), and 120 min (group C), both the bronchus affected by the carcinoma and the contralateral bronchus were biopsied. Of the 34 patients, 24 had histologically proven carcinoma and were enrolled in the study. Etanidazole determination was carried out with a polarographic method both in plasma and tissue. The results obtained indicate that the most favorable concentration of etanidazole in the tissue is at 30 min after administration and at this point is most beneficial when associated with radiotherapy. The tumor/plasma ratio of etanidazole examined in three phases is relatively higher than that noted with HPLC; however, it is compatible with the methodology used and previous studies carried out on other tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0360-3016
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
585-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Kinetic uptake of etanidazole in lung carcinoma and normal tissue in vivo.
pubmed:affiliation
Radiotherapy Department, Malpighi Hospital, Bologna, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't